16 days ago • Posted by William Ramstein

Keep an eye out for biotech IPOs

"Valuation step-ups at exit also had a robust year, with public listing step-ups improving YoY to 1.4x, while the acquisition step-up held at 1.7x—approximately the 10-year average. The strength in 2020's public equity multiples buoyed these step-ups, especially on the public listing front and specifically in relation to growth businesses."

Source: pitchbook

bg_nwsletter